30 December 2008
Soluble cytokine receptors sTNFR I and sTNFR II, receptor antagonist IL-1ra, and anti-inflammatory cytokines IL-10 and IL-13 in the pathogenesis of systemic inflammatory response syndrome in the course of burns in children
Janusz Piotr SikoraACDEF, Wojciech KuzańskiBF, Ewa AndrzejewskaBDGMed Sci Monit 2009; 15(1): CR26-31 :: ID: 869529
Abstract
Background
This is a prospective clinical study focusing on cytokine inhibitors (sTNFR I, sTNFR II, IL-1ra) and anti-inflammatory cytokines (IL-10, IL-13) following burn injury in children. The aim of the study was to evaluate the prognostic values of the selected cytokine-related molecules.
Material and Method
Fifty-one patients (29 burned children and 22 controls) admitted to the Department of Pediatric Surgery and Oncology were included in this study. Serum sTNFR I, sTNFR II, IL-1ra, IL-10, IL-13, and CRP concentrations were evaluated twice using ELISA, the first determination being performed within 6-24 hrs after the burn and the second following completion of treatment and normalization of the CRP level.
Results
With the exception of IL-13, significantly higher cytokine and cytokine inhibitor levels were observed within 6-24 hours after burn compared with controls (p<0.05). Moreover, a significant attenuation of the burn-induced increases in sTNFR I, sTNFR II, IL-1ra, and IL-10 concentrations was recorded after burn therapy (p<0.05). TNF-alpha soluble receptor levels correlated significantly with serum CRP concentrations. Similarly, the levels of sTNFR I, sTNFR II, and IL-1ra significantly correlated with TBSA of the burned children.
Conclusions
The results confirm the involvement of these markers in the pathogenesis of SIRS in this clinical entity. Their monitoring simultaneously with CRP level allows evaluating the generalized inflammatory response and may clinically support diagnostic and prognostic methods.
Keywords: Receptors, Tumor Necrosis Factor, Type II - blood, Receptors, Tumor Necrosis Factor, Type I - blood, Systemic Inflammatory Response Syndrome - etiology, Prospective Studies, Poland, Interleukin-13 - blood, Interleukin-10 - blood, Interleukin 1 Receptor Antagonist Protein - blood, Enzyme-Linked Immunosorbent Assay, Child, Preschool, Child, C-Reactive Protein - metabolism, Adolescent, Burns - complications
Editorial
01 March 2025 : Editorial
Editorial: The World Health Organization (WHO) Updated List of Emerging and Potentially Pandemic Pathogens Includes Yersinia pestis as Plague Vaccines Await Clinical TrialsDOI: 10.12659/MSM.948672
Med Sci Monit 2025; 31:e948672
In Press
Clinical Research
Impact of Nurse-Led Versus Surgeon-Led Preoperative Counseling and Follow-Up on Postoperative Outcomes in P...Med Sci Monit In Press; DOI: 10.12659/MSM.945597
Clinical Research
Evaluation of Attitudes to Learning Doctor-Patient Communication Skills in 427 Postgraduate Doctors Using t...Med Sci Monit In Press; DOI: 10.12659/MSM.947276
Clinical Research
Exploring the Association Between Serum Neurogranin, Nardilysin, and Ischemic Stroke: A Case-Control Study ...Med Sci Monit In Press; DOI: 10.12659/MSM.947703
Clinical Research
Comparative Analysis of Laser Therapies for Striae Distensae: Fractional CO₂ vs Combined Q-Switch Nd:YAGMed Sci Monit In Press; DOI: 10.12659/MSM.947464
Most Viewed Current Articles
17 Jan 2024 : Review article 7,036,157
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
16 May 2023 : Clinical Research 702,298
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Mar 2024 : Editorial 27,491
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and ...DOI :10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
28 Jan 2024 : Review article 21,680
A Review of IgA Vasculitis (Henoch-Schönlein Purpura) Past, Present, and FutureDOI :10.12659/MSM.943912
Med Sci Monit 2024; 30:e943912